News Teva buys US rights to Celltrion biosimilars Israeli firm buys rights to near-copies of Roche blockbusters.
News Pfizer's breast cancer drug step closer to EU approval Ibrance is already Pfizer's top oncology product.
Cancer Lilly’s wait for breast cancer data will help rivals Setback for Lilly as it looks to develop best-in-class product
Cancer Novartis’ breast cancer drug LEEO11 gains breakthrough statu... Drug will challenge Pfizer's Ibrance
Partner Content Partner Content Ibrance approval cemented as competition comes into view In February 2015, Pfizer's Ibrance (palbociclib) was granted accelerated approval by the FDA for treatment of newly diagnosed HR+ (hormone receptor positive) / HER2- breast cancer in post-men
News Kyverna builds case for CAR-T in stiff person syndrome Kyverna has data with miv-cel in stiff person syndrome that shows durable efficacy and safety and seems to sidestep issues flagged with other CAR-Ts.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
